pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA
Olema Pharmaceuticals
Olema Pharmaceuticals patent portfolio — 8 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Chennai, IN
- Employees
- 2
- Programs
- 7
- Drugs
- 17
- Patents
- 8
Olema Pharmaceuticals patents
8 pharmaceutical patents indexed for Olema Pharmaceuticals. 0 expire within 24 months.
Olema Pharmaceuticals has 8 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12428379
Acylsulfonamide KAT6A inhibitors
granted -
US 12370181
Regimens of estrogen receptor antagonists
granted -
US 11672785
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 11229630
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10624878
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
granted -
US 10292971
Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs
granted -
US 9018244
Benzopyran compounds, compositions and uses thereof
granted -
US 8071545
Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
granted
Frequently asked questions
How many patents does Olema Pharmaceuticals have?
8 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Olema Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.